Co-Authors
This is a "connection" page, showing publications co-authored by MENASHE BAR ELI and COLIN P DINNEY.
Connection Strength
1.279
-
Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res. 2008 Mar 01; 14(5):1478-86.
Score: 0.327
-
Targeting EGFR in bladder cancer. World J Urol. 2007 Dec; 25(6):573-9.
Score: 0.157
-
Receptor heterodimerization: a new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancer. J Urol. 2011 Feb; 185(2):693-700.
Score: 0.099
-
miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res. 2009 Aug 15; 15(16):5060-72.
Score: 0.090
-
Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer? J Urol. 2008 Sep; 180(3):1146-53.
Score: 0.084
-
Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol. 2008 Jan; 179(1):353-8.
Score: 0.080
-
Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res. 2006 Aug 01; 12(15):4671-7.
Score: 0.073
-
Focus on bladder cancer. Cancer Cell. 2004 Aug; 6(2):111-6.
Score: 0.064
-
Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. Clin Cancer Res. 2003 Aug 01; 9(8):3167-75.
Score: 0.059
-
Nuclear factor-kappaB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8. Clin Cancer Res. 2003 Jul; 9(7):2786-97.
Score: 0.059
-
Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res. 2000 May; 6(5):2104-19.
Score: 0.047
-
Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res. 2000 Apr 15; 60(8):2290-9.
Score: 0.047
-
Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. Lab Invest. 2008 Jul; 88(7):694-721.
Score: 0.021
-
Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. Cancer Res. 2007 Feb 15; 67(4):1430-5.
Score: 0.019
-
Molecular correlates of gefitinib responsiveness in human bladder cancer cells. Mol Cancer Ther. 2007 Jan; 6(1):277-85.
Score: 0.019
-
Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Cancer Res. 2005 Nov 15; 65(22):10524-35.
Score: 0.017
-
The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther. 2004 Mar; 3(3):279-90.
Score: 0.015